{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:40:03Z","timestamp":1793742003892,"version":"4.6.1"},"reference-count":55,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cells directed against B-cell maturation antigen (BCMA) are an effective treatment for multiple myeloma (MM), but short persistence and frequent relapses are challenges for this immunotherapy. This lack of durability has been attributed to the premature terminal differentiation of CAR T cells, which prevents the formation of long-lived memory cells that maintain antitumor responses. To improve long-term efficacy, we used CRISPR\/CRISPR-associated protein 9-mediated gene editing to ablate the expression of the transcription factor Blimp-1. Blimp-1 knockout (KO) CAR T cells displayed a memory-like phenotype compared with control (Mock) CAR T cells, but had reduced effector function, with a striking loss of granzyme B. However, in a murine model of advanced MM, Blimp-1 KO CAR T cells effectively slowed or even prevented disease progression, significantly outperforming Mock CAR T cells in improving survival (P\u00a0=\u00a0.006). To understand this enhanced in\u00a0vivo effectiveness, Blimp-1 KO CAR T cells were characterized after being repeatedly challenged with tumor cells in\u00a0vitro. In this setting, Blimp-1 KO CAR T cells maintained a highly active state with high expression of memory markers, but, crucially, demonstrated enhanced effector function and increased energetic capacity. RNA-sequencing analysis of tumor-exposed Blimp-1 KO CAR T cells confirmed the presence of a memory-like transcriptomic signature and, additionally, revealed enhanced ribosome biogenesis and repressed CAR T-cell dysfunction as mechanisms that could contribute to improved antitumor activity. Put together, our findings show that dampening Blimp-1 expression altered the phenotype and function of anti-BCMA CAR T cells, leading to augmented therapeutic efficacy in MM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013209","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T20:50:22Z","timestamp":1733518222000},"page":"627-641","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-0639","authenticated-orcid":false,"given":"Anthony M.","family":"Battram","sequence":"first","affiliation":[{"name":"1Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7227-9712","authenticated-orcid":false,"given":"Joan","family":"Ma\u00f1\u00e9-Pujol","sequence":"additional","affiliation":[{"name":"1Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"2Faculty of Medicine and Medical Sciences, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1752-3081","authenticated-orcid":false,"given":"David F.","family":"Moreno","sequence":"additional","affiliation":[{"name":"1Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"3Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-5420","authenticated-orcid":false,"given":"Aina","family":"Oliver-Cald\u00e9s","sequence":"additional","affiliation":[{"name":"1Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"3Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Carpio","sequence":"additional","affiliation":[{"name":"1Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-5423","authenticated-orcid":false,"given":"Oriol","family":"Cardus","sequence":"additional","affiliation":[{"name":"1Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"2Faculty of Medicine and Medical Sciences, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-0921","authenticated-orcid":false,"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[{"name":"1Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"3Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Urbano-Ispizua","sequence":"additional","affiliation":[{"name":"1Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"3Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"},{"name":"4Josep Carreras Leukaemia Research Institute, Barcelona, Spain"},{"name":"5Department of Hematology, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[{"name":"1Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"2Faculty of Medicine and Medical Sciences, University of Barcelona, Barcelona, Spain"},{"name":"3Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"},{"name":"5Department of Hematology, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"issue":"10272","key":"2025032119373238900_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"2025032119373238900_bib2","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.3390\/cancers13194787","article-title":"Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma","volume":"13","author":"Ackley","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"2025032119373238900_bib3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.17888","article-title":"Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period","volume":"196","author":"Rodr\u00edguez-Lobato","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2025032119373238900_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"May","key":"2025032119373238900_bib5","doi-asserted-by":"crossref","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"2025032119373238900_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2025032119373238900_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"June","key":"2025032119373238900_bib8","doi-asserted-by":"crossref","first-page":"1149138","DOI":"10.3389\/fphar.2023.1149138","article-title":"Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed\/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials","volume":"14","author":"Hu","year":"2023","journal-title":"Front Pharmacol"},{"issue":"8","key":"2025032119373238900_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025032119373238900_bib10","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B\u00a0cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"2025032119373238900_bib11","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"2025032119373238900_bib12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"2025032119373238900_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2025032119373238900_bib14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"2025032119373238900_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"issue":"7","key":"2025032119373238900_bib16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol Cell Biol"},{"issue":"12","key":"2025032119373238900_bib17","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"2025032119373238900_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"2025032119373238900_bib19","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov"},{"issue":"39","key":"2025032119373238900_bib20","doi-asserted-by":"crossref","first-page":"eabo0514","DOI":"10.1126\/sciadv.abo0514","article-title":"CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome","volume":"8","author":"Rodriguez-Marquez","year":"2022","journal-title":"Sci Adv"},{"issue":"19","key":"2025032119373238900_bib21","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"14","key":"2025032119373238900_bib22","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood.2021012714","article-title":"Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy","volume":"139","author":"Yoshikawa","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119373238900_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated results from the phase I CRB-402 Study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119373238900_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-142695","article-title":"Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119373238900_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136748","article-title":"Orvacabtagene autoleucel (orva-cel; JCARH125): a fully human BCMA-targeted second-generation CAR T cell product characterized by a predominant central memory phenotype with high in\u00a0vitro and in\u00a0vivo proliferative potential and sustained in\u00a0vivo persistenc","volume":"136","author":"Colonna","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119373238900_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-134378","article-title":"Idecabtagene vicleucel (ide-cel, bb2121) responses are characterized by early and temporally consistent activation and expansion of CAR T cells with a T effector phenotype","volume":"136","author":"Martin","year":"2020","journal-title":"Blood"},{"key":"2025032119373238900_bib27","doi-asserted-by":"crossref","first-page":"805260","DOI":"10.3389\/fimmu.2021.805260","article-title":"Conserved and unique functions of Blimp1 in immune cells","volume":"12","author":"Nadeau","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"2025032119373238900_bib28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ni1320","article-title":"Transcriptional repressor Blimp-1 regulates T cell homeostasis and function","volume":"7","author":"Martins","year":"2006","journal-title":"Nat Immunol"},{"issue":"5","key":"2025032119373238900_bib29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/ni1321","article-title":"Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance","volume":"7","author":"Kallies","year":"2006","journal-title":"Nat Immunol"},{"issue":"2","key":"2025032119373238900_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.immuni.2009.06.021","article-title":"Blimp-1 transcription factor is required for the differentiation of effector CD8+ T cells and memory responses","volume":"31","author":"Kallies","year":"2009","journal-title":"Immunity"},{"issue":"2","key":"2025032119373238900_bib31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2009.05.014","article-title":"Transcriptional repressor Blimp-1 promotes CD8+ T cell terminal differentiation and represses the acquisition of central memory T cell properties","volume":"31","author":"Rutishauser","year":"2009","journal-title":"Immunity"},{"issue":"2","key":"2025032119373238900_bib32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.immuni.2009.06.019","article-title":"A\u00a0role for the transcriptional repressor Blimp-1 in CD8+ T cell exhaustion during chronic viral infection","volume":"31","author":"Shin","year":"2009","journal-title":"Immunity"},{"issue":"4","key":"2025032119373238900_bib33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.immuni.2013.08.032","article-title":"Epigenetic modifications induced by Blimp-1 regulate CD8+ T cell memory progression during acute virus infection","volume":"39","author":"Shin","year":"2013","journal-title":"Immunity"},{"issue":"670","key":"2025032119373238900_bib34","doi-asserted-by":"crossref","first-page":"eabn7336","DOI":"10.1126\/scitranslmed.abn7336","article-title":"BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion","volume":"14","author":"Jung","year":"2022","journal-title":"Sci Transl Med"},{"issue":"1","key":"2025032119373238900_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3324\/haematol.2019.228577","article-title":"Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma","volume":"106","author":"Perez-Amill","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"2025032119373238900_bib36","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41587-022-01639-x","article-title":"Massively parallel knock-in engineering of human T cells","volume":"41","author":"Dai","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2025032119373238900_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.omtm.2022.06.010","article-title":"T\u00a0cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells","volume":"26","author":"Battram","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"14","key":"2025032119373238900_bib38","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3390\/cancers13143534","article-title":"IL-15 enhances the persistence and function of BCMA-targeting CAR-T cells compared to IL-2 or IL-15\/IL-7 by limiting CAR-T cell dysfunction and differentiation","volume":"13","author":"Battram","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"2025032119373238900_bib39","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.celrep.2015.08.049","article-title":"TCF1 is required for the T follicular helper cell response to viral infection","volume":"12","author":"Wu","year":"2015","journal-title":"Cell Rep"},{"issue":"10","key":"2025032119373238900_bib40","doi-asserted-by":"crossref","first-page":"e76781","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2025032119373238900_bib41","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2005-12-4827","article-title":"Differential regulation of T-cell growth by IL-2 and IL-15","volume":"108","author":"Cornish","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2025032119373238900_bib42","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41590-019-0495-x","article-title":"Quantitative analysis of T cell proteomes and environmental sensors during T cell differentiation","volume":"20","author":"Howden","year":"2019","journal-title":"Nat Immunol"},{"issue":"6","key":"2025032119373238900_bib43","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.cmet.2020.11.007","article-title":"SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution","volume":"32","author":"Arg\u00fcello","year":"2020","journal-title":"Cell Metab"},{"issue":"5312","key":"2025032119373238900_bib44","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1126\/science.276.5312.596","article-title":"Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation","volume":"276","author":"Lin","year":"1997","journal-title":"Science"},{"issue":"4","key":"2025032119373238900_bib45","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.4049\/jimmunol.181.4.2338","article-title":"Blimp-1 attenuates Th1 differentiation by repression of ifng, tbx21, and bcl6 gene expression","volume":"181","author":"Cimmino","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"2025032119373238900_bib46","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2025032119373238900_bib47","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat Commun"},{"key":"2025032119373238900_bib48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2021.10.016","article-title":"IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors","volume":"524","author":"Zou","year":"2022","journal-title":"Cancer Lett"},{"issue":"25","key":"2025032119373238900_bib49","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"issue":"21","key":"2025032119373238900_bib50","doi-asserted-by":"crossref","first-page":"11884","DOI":"10.1128\/JVI.01461-13","article-title":"Cytokine-dependent induction of CD4\u00a0+ T cells with cytotoxic potential during influenza virus infection","volume":"87","author":"Hua","year":"2013","journal-title":"J\u00a0Virol"},{"issue":"6","key":"2025032119373238900_bib51","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2025032119373238900_bib52","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/ni.3410","article-title":"A\u00a0molecular threshold for effector CD8+ T cell differentiation controlled by transcription factors Blimp-1 and T-bet","volume":"17","author":"Xin","year":"2016","journal-title":"Nat Immunol"},{"issue":"10","key":"2025032119373238900_bib53","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/eji.201847771","article-title":"Blimp-1 induces and Hobit maintains the cytotoxic mediator granzyme B in CD8\u00a0T cells","volume":"48","author":"Kragten","year":"2018","journal-title":"Eur J Immunol"},{"issue":"10","key":"2025032119373238900_bib54","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.4049\/jimmunol.1001682","article-title":"PRDM1\/Blimp-1 controls effector cytokine production in human NK cells","volume":"185","author":"Smith","year":"2010","journal-title":"J\u00a0Immunol"},{"issue":"28","key":"2025032119373238900_bib55","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1038\/s41388-020-1347-8","article-title":"The BLIMP1\u2014EZH2 nexus in a non-Hodgkin lymphoma","volume":"39","author":"Anderson","year":"2020","journal-title":"Oncogene"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/627\/2354323\/blooda_adv-2024-013209-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/627\/2354323\/blooda_adv-2024-013209-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:13:04Z","timestamp":1742587984000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/3\/627\/534348\/Genetic-disruption-of-Blimp-1-drastically-augments"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013209","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]}}}